Nontypeable haemophilus influenzae polypeptides
SUBSTANCE: there are described polypeptides eliciting an immune response on H.influenzae. There is offered an antibody selectively binding specified polypeptides. The invention also concerns an immunogenic composition containing the described polypeptides.
EFFECT: invention can be used in medicine for treating or preventing a disease or an infection caused by Hinfluenzae, such as otitis media.
9 cl, 3 tbl
The text descriptions are given in facsimile form.
1. Polypeptide that causes an immune response against .influenzae containing amino acid sequence having sequence identity, component, at least 90%, in relation to one or more of SEQ ID NO:1566, 1570, 1938, 2368, 3310, 3520, 5088, 5089 and 5090.
2. The polypeptide according to claim 1, applicable as a medicine.
3. The antibody selectively binding to a polypeptide according to claim 1 or 2, obtained by immunization of a mammal a polypeptide according to claim 1 or 2.
4. The antibody according to claim 3, whereby the antibody is a monoclonal antibody.
5. The antibody according to claim 3 or 4, applicable as a medicine.
6. Immunogenic composition comprising (a) a polypeptide and/or antibody according to any one of the preceding paragraphs; and (b) a pharmaceutically acceptable carrier.
7. The composition according to claim 6, further containing adjuvant vaccine.
8. The use of the polypeptide or antibody according to any one of claims 1 to 5 in the manufacture of a medicinal product for treatment or prevention of diseases and/or infections caused by .influenzae.
9. The use of claim 8 for the prevention of otitis media, bronchitis, conjunctivitis, sinusitis, infecti the urinary tract, pneumonia, bacteremia, septic arthritis, epiglottitis, empyema, pericarditis, cellulitis, osteomyelitis, or meningitis.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biotechnology. Immunogenic composition is described comprising an effective amount of a combination of at least two different proteins or their immunogenic fragments selected from at least two groups of proteins or immunogenic fragments selected from the following groups: group (a): at least one staphylococcal protein binding an extracellular component, or its immunogenic fragment; group (b): at least one staphylococcal transport protein or its immunogenic fragment; group (c): at least one staphylococcal regulator of virulence, toxin or its immunogenic fragment, wherein at least one protein or an immunogenic fragment is selected from the group (a), and at least one protein or immunogenic fragment is selected from the group (b). A vaccine against staphylococcal infection is proposed, which comprises an effective amount of the immunogenic composition described. Also the method to obtain the vaccine is offered.
EFFECT: method for preventing or treating staphylococcal infection is proposed, comprising the introduction of the proposed vaccine, as well as method of producing immunoglobulin, comprising the steps of immunisation of the recipient by the proposed vaccine.
17 cl, 7 dwg, 8 tbl, 8 ex
SUBSTANCE: there is produced a new CT-F5/H3 hybrid cell clone producing monoclonal cholera toxin antibody (MCAB) in the environment of cell culture and abdominal cavity of syngeneic animals. The clone is produced by the fusion of mouse myeloma SP-2/0 cells with popliteal lymph node cells of BALB/c mice immunised with a commercial preparation of cholera toxin (SIGMA) in posterior pads. A fusing agent is polyethylene glycol of molecular weight 4000. Hybridoma selection has been performed on Dulbecco modified Eagle's medium with bovine foetal serum and hypoxantine-aminopterin-thymidine added. Hybridoma synthesises MCAB specifically interacting with cholera toxin and not interacting with thermolabile E.coli toxin. The antibody titre reaches 1:20000 1:40000 in the cultural fluid, 1:4000000 in ascitic.
EFFECT: antibodies can be used for designing immunobiological systems of cholera toxin detection exceeding available analogues in sensitivity.
2 dwg, 4 ex
SUBSTANCE: there is produced a new CT-E6/E10 hybrid cell clone producing monoclonal cholera toxin antibody in the environment of cell culture and abdominal cavity of syngeneic animals. The clone is produced by the fusion of mouse myeloma SP-2/0 cells with popliteal lymph node cells of BALB/c mice immunised with a commercial preparation of cholera toxin (SIGMA) in posterior pads. A fusing agent is polyethylene glycol of molecular weight 4000. Hybridoma selection has been performed on Dulbecco modified Eagle's medium with bovine foetal serum and hypoxantine-aminopterin-thymidine added. Hybridoma synthesises monoclonal antibodies specifically interacting with cholera toxin and not interacting with thermolabile E.coli toxin. The antibody titre reaches 1:10000 in the cultural fluid, 1:1000000 in ascitic.
EFFECT: produced antibodies exceeds the analogues available in sensitivity.
2 dwg, 4 ex
SUBSTANCE: essence of invention includes contact of liquid sample, taken from mammal organism, with one or several monoclonal antibodies to Lawsonia intracellularis antigen, secreted by cell lines of ECACC hybridomes, which have registration numbers. Invention also includes diagnostic test-kit, containing antibodies specific for Lawsonia intracellularis.
EFFECT: increased specificity of antigen detection.
11 cl, 5 ex, 5 dwg
SUBSTANCE: method facilitates linkage of sequences, coding immunoglobulin variable regions, T-cells receptors or B-cells receptors. Method is instrument of higher effectivity for making sequence data libraries. Capability of multiple RT-PCR with chain extension by interruption with employment of matrix, derived from single cell, provides highly effective creation of sister pairs libraries.
EFFECT: method is effective for linkage of two or few nucleotide sequences, coding domens or subunits of heteromeric protein as a result of single reaction performance.
51 cl, 25 dwg, 27 tbl, 14 ex
SUBSTANCE: invention concerns biotechnology. There is described application of antibody to acetyl-CoA-acetyltransferase or its antigen-binding fragment in manufacturing of a medical product for treatment or prevention of the infection caused by Clostridium difficile and Enterococcus faecalis, faecium is described. There is disclosed combined preparation for treatment of the infection caused by Clostridium difficile containing (i) antibody to acetyl-CoA-acetyltransferase or its antigen-binding fragment; and (ii) at least one antibiotic from the group consisting of gentamycin, vancomycin and metronidazole. There is presented inhibitor of acetyl-CoA-acetyltransferase representing antibody or its antigen-binding fragment, containing at least one component of the group consisting of (i) complementarity determining regions (CDR) of 1-3 VH-chain; and (ii) complementarity determining regions (CDR) of 3 VL-chain. There is described method of treating the infection caused by Clostridium difficile, including introduction of therapeutically effective amount of antibody to acetyl-CoA-acetyltransferase to the medically indigent patient.
EFFECT: invention allows for prevention and treatment of the infection caused by bacteria Clostridium difficile and Enterococcus faecalis, faecium.
43 cl, 6 tbl
SUBSTANCE: method of preparing diagnostic agglutinating serum for pathogenic Yersinia strains involves hyperimmunisation of rabbits with antigen representing 0.4-0.6% formalin inactivated antigen (pYV+) of Yersinia enterocolitica My 03R strain into auricular cranial vein. Immunisation of rabbits with said antigen is fourfold in dosage as follows: 290-310 million kl/ml, 490-510 million kl/ml, 0.99-1.1 billion kl/ml and 1.9-2.1 billion kl/ml, respectively with dosage interval 6-7 days. Further the producer is examined for immunogenic properties. Serum separated from the sampled blood is preserved.
EFFECT: method ensures preparation of high-quality agglutinating serum used in yersiniosis diagnostics in animals.
SUBSTANCE: invention describes monoclonal antibody directed against GNA33 peptide with definite amino acid sequence, which demonstrates complement-mediated bactericidal and/or opsonic activity against bacteria Neisseria meningitides of serogroup B (MenB). On the basis of monoclonal antibody composition for treatment and prevention of MenB disease has been constructed, and application of composition favours production of immune response against said bacteria after its introduction into organism of subject-mammal. According to invention monoclonal antibody can also be used for isolating molecular mimetic of epitope of bacteria Neisseria meningitides of serogroup B (MenB) by antibody contact with supposed mimetic and isolation of formed antibody-mimetic complex.
EFFECT: according to invention antibodies and based on them compositions can be efficiently used for prevention of MenB disease, as well as for diagnostics of MenB infection.
5 cl, 9 dwg, 6 tbl, 5 ex
FIELD: chemistry; biochemistry.
SUBSTANCE: invented here are proteins of the meningococcus bacteria Neisseria meningitides (mainly strain B), with immunogenic properties. The proteins have defined amino acid sequences, presented in the description, and are coded with corresponding nucleotide sequences. Description is also given of an antibody, specific to the indicated meningococcus proteins. These proteins, coding their nucleotide sequences, as well as the specific antibody, can be used as an active ingredient in compositions for treating or preventing infection caused by Neisseria meningitides. The presented proteins can be used as antigens for making effective vaccines, immunogenic compositions.
EFFECT: obtaining proteins, used as ingredients for making effective vaccines, immunogenic compositions.
11 cl, 2 tbl, 104 ex
FIELD: medicine; biotechnologies.
SUBSTANCE: amino-acid sequences are presented in the list of the sequences obtained from a bacterium, mainly strains A and B which show properties of an antigene. The invention includes corresponding nucleotide sequences of fragments of the nucleinic acid, coding amino-acid sequences of the specified proteins. The proteins under the invention can be used as antigenes for obtaining of specific antibodies and manufacturing of compositions for treatment, preventive maintenance or diagnostics of the infection caused Neisseria meningitidis. The compositions are prepared on the basis of a protein, a fragment of nucleinic acid or an antibody with addition of the pharmaceutically comprehensible carrier and represent vaccinal, diagnostic or pharmaceutical compositions. Sequences of the obtained proteins have no any considerable homology with sequences Neisseria gonorrhoeae, that allows to receive treatment-and-prophylactic and diagnostic compositions with high specificity in relation to N. meningitidis and also to receive Diagnostic reagents for differentiation N. meningitidis from N. gonorrhoeae.
EFFECT: efficiency of application.
12 cl, 2 tbl, 17 ex
SUBSTANCE: polypeptides or proteins in double-strand form are obtained via recombinant expression in E. coli host cells. The polypeptide or protein exhibits its biological activity in form of a double-strand polypeptide or protein; C-terminal amino acid group of the first strand is an Arg or Lys'groups; the second protein/polypeptide strand has in its N-end 1-20 amino acid groups and a VPXGS (PRS) pentapeptide sequence, where X denotes any naturally occurring amino acid, where V - Val, Leu, He, Ala, Phe, Pro or Gly, P - Pro, Leu, He, Ala, Phe, Val or Gly, G - Gly, Leu, lie, Ala, Pro, Phe or Val, and S denotes Ser, Tyr, Trp or Thr. The method of obtaining the disclosed product involves the following steps: modification of the polypeptide or protein on the nucleic acid level, so that said polypeptide or protein in its modified form contains a VPXGS sequence in its loop area, where X, V, P, G and S are as defined above; incorporation of a structure modified at the nucleic acid level into the E. coli cell; culturing and then lysis of host cells and separation of the double-strand polypeptide or protein which is, for example, a botulinum neurotoxin, particularly type A botulinum neurotoxin (BoNT(A)).
EFFECT: obtained proteins and polypeptides provide cytotoxic effect in small dosages.
23 cl, 9 dwg, 7 ex
SUBSTANCE: biologically active peptide is proposed with the common formula: , where OBu - residue of 2-oxobutyric acid, Abu - residue of 2-aminobutyric acid, Dha - residue of 2,3-didehydroalanine, Dhb - residue of 2,3-didehydroaminobutyric acid, besides residues are in sequence linked with amide links, residues Abu3-Ala7, Abu22-Ala27 and Abu24-Ala31 are also linked pairwise with thioether links with formation of three residues of 3-methyllanthionine, residues Ala11-Ala21 are linked with thioether link to form residue of lanthionine. This peptide has antimicrobial effect at gram-positive bacteria Bacillus subtilis, strains L1 and 1621; Bacillus pumilus, strain 2001; Bacillus globigii, strain I; Bacillus amyloliquefaciens, strain I; Bacillus megaterium, strain VKM41; Mycobacterium smegmatis, strain 1171; Mycobacterium phlei, strain 1291; Micrococcus luteus, strain B 1314; Staphylococcus aureus, strain 209p; Rhodococcus sp., strain SSI.
EFFECT: increased efficiency of peptide antimicrobial action.
4 dwg, 1 tbl, 6 ex
SUBSTANCE: described is a peptide having antimicrobic action, which has general formula: , where OBu is a 2-oxobutyric acid residue, Abu is a 2-aminobutyric acid residue, Dha is a 2,3-didehydroanaline residue, Dhb is a 2,3-didehydroaminobutyric acid residue, where residues in the sequence are joined by amide bonds, residues Ala7 and Ala11, Ala19 and Ala23 are joined in pairs by thioester bonds to form two lanthionine (Lan) residues, Abu25 and Ala28, Abu29 and Ala32 are joined in pairs by thioester bonds to form two 3-methyllanthionine (MeLan) residues.
EFFECT: high antimicrobic action of the peptide.
4 dwg, 1 tbl, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: to obtain microbe-resistant plants plant cells are transformed with vector, which contains polynucleotide structure, which codes defensin polypeptide, which has amino-acid sequence C-x (3)-C-x (7, 9)-C-C, C-C-(8)-C-x-C and C-x-C-x (8, 11)- C.
EFFECT: obtaining polypeptide, which can be also applied as drug or veterinary medication, as well as in forage for animals.
23 cl, 4 tbl, 6 ex
SUBSTANCE: invention concerns medicine, namely to creation of immunogene compositions and vaccines for prevention or treatment of the infections caused by Gram-negative bacteria. The immunogene compositions containing a transferrin-binding fiber and Hsf, and a way of their reception are offered. It is shown, that the combination of these two antigens synergically influences on production of antibodies with high activity in the analysis of bactericidal Serum. The composition can be used in vaccines against Gram-negative bacteria, including Neisseria meningitides, Neisseria gonorrhoeae.
EFFECT: creation of immunogene compositions and vaccines for prevention or treatment of the infections caused by Gram-negative bacteria.
56 cl, 10 ex, 1 dwg
FIELD: medicine, microbiology.
SUBSTANCE: invention concerns nucleotide sequence coding TolC, and also to certain amino-acid sequence which is built in in permissive, located from lateral aspect of a membrane area of TolC. In the invention is described a plasmid, containing a nucleotide sequence, for an expression of the merged protein or merged peptide. The invention concerns also the transformed bacterium, in particular enterobacteria, to its use as a part of a pharmaceutical composition for stimulation of the immune response and in a diagnostic set for detection of interesting substance in an organism. The framed transport system provides high efficiency of presentation of a product of an expression in an external cellular membrane of a bacterium.
EFFECT: provision of high efficiency of presentation of product of expression in external cellular membrane of a bacterium.
13 cl, 1 dwg, 5 ex
SUBSTANCE: invention relates to polypeptides with established amino acid sequence, which have antimicrobial activity. Amino acid polypeptide sequence has 65-99% of identity with amino acid sequence of polypeptide, originating, particularly, from strain Pszudoplectania nigrella CBS 444.97. Invention also relates to polynucleotide, which has nucleotide sequence, coding said polypeptide, constructions of nucleic acid, recombinant expression vector, which contains said construction, and recombinant host-cell, intended for obtaining said polypeptide. In invention methods of obtaining polypeptide and inhibiting microbe cell growth using said polypeptide are described. According to invention polypeptides can be used for production of veterinary or therapeutic medication for treatment or prevention of microbial infection in humans and animals. According to invention polypeptide with antimicrobial properties ensures stability of antimicrobial activity when used in different forms of antimicrobial medications.
EFFECT: obtaining polypeptides with antimicrobial properties.
19 cl, 3 tbl, 8 ex
FIELD: medicine; pharmacology.
SUBSTANCE: invention group refers to compositions containing hapten-carrier conjugate within arranged and repeating matrix, and method of related composition production. Offered hapten-carrier conjugate used for induction of agent-specified immune reaction in case of addiction or abuse, contains cortex particle including at least one first apposition site, where specified cortex particle is virus-like particle of RNA-phage, and at least one nicotine hapten with at least one second apposition site, where specified second apposition site is associated by at least one covalent non-peptide bond with specified first apposition site, thus forming arranged and repeating hapten-carrier conjugate. Offered conjugates and compositions under this invention can include virus-like particles connected to various haptens including hormones, toxins and agent, especially agents causing addiction, as nicotine and can be applied for induction of hapten immune reaction for therapeutic, preventive and diagnostic purposes.
EFFECT: vaccines can induce stable immune reactions for nicotine and fast reduce nicotine availability for brain absorbing.
31 cl, 6 dwg
FIELD: molecular biology, veterinary.
SUBSTANCE: invention proposes isolated DNA sequence (variants) encoding Ehrlichia canis protein of size 30 kDa. Also, invention proposes vector comprising such sequence, recombinant Ehrlichia canis 28 kDa protein encoded by this sequence, a cell-host comprising this sequence, a method for preparing the protein, immunoreactive antibody specific to this protein and a method for inhibition of Ehrlichia canis infection in subject. Recombinant protein of size 28 kDa from Ehrlichia canis shows immune reactivity with respect to serum against Ehrlichia canis. Proposed group of inventions can be used in development of vaccines and serodiagnosticum that shows high effectiveness for prophylaxis of diseases and for carrying out the serodiagnosis.
EFFECT: improved preparing method, valuable medicinal and veterinary properties of protein.
19 cl, 17 dwg, 8 ex
FIELD: biotechnology, medicine, in particular treatment, prevention and diagnosis of diseases, associated with Neisseria meningitides.
SUBSTANCE: Claimed protein includes one or more N. meningitides protein fragments with known amino acid sequences, wherein said fragment contains one or more antigen determinants and has not more than 1977 amino acid from SEQ ID NO:1 and/or not more than 1531 amino acid from SEQ ID NO:2 which are described in specification with the proviso, that general protein sequence is not characterized by amino acid sequences represented in NO:1 and NO:2. Each claimed protein is encoded by nuclear acid (NA) with nucleotide sequence that defines protein amino acid sequence according to gene code. Peptides and nuclear acid of present invention are useful in drug production for treatment and prophylaxis of infections induced neisseria, as well as in production of diagnostic reagent for detection of neisseria or specific antibodies. Aldo disclosed is peptide- or NA-based pharmaceutical composition in effective amount with acceptable carrier. Said composition is useful for treatment of N. meningitides mediated infection. For prophylaxis composition is applied in vaccine form. Invention makes it possible to overcome diversity of neisseria antigen properties.
EFFECT: improved method for neisseria infection prophylaxis and treatment.
24 cl, 2 tbl
SUBSTANCE: there is developed a complex containing a V3-loop gpl20 and Tat HIV. There is disclosed a set containing such complex and a method of developing an immune response by means of such complexes. The invention can be used in medicine.
EFFECT: complex exhibits high immunogenicity that allows using it for treating or preventing HIV-infection.
27 cl, 3 tbl, 10 ex